APPENDIX Common Slang Names for Misused Drugs
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
Medical Marijuana, Illicit Marijuana and Mr. C
Medical Marijuana, Illicit Marijuana and Mr. C In late 2013, word came out that New York State was looking into legalizing medical marijuana for treatment of certain serious symptoms that arise from certain serious medical conditions. Among the symptoms and medical conditions to be included were muscle spasms in multiple sclerosis patients. Since multiple sclerosis is my specialty, both professionally and personally, I decided to write this article to help educate people about medical marijuana. I. My Experience with Marijuana as a Street Drug Until sometime in the recent past, I had had minimal experience with the world of marijuana. I know I had smelled something weird at several concerts that I went to when I was in college. My friends told me that it wasn’t marijuana but rather “herb cigarettes.” They told me that they were sold in a store in CollegeTown by a Ms. Jayne. One time, my friend asked if I could drive him to CollegeTown so he could get more “herb cigarettes.” When we got there, my friend told me that he would go purchase them and that I should wait in the car. I thought “whatever” because I knew smoking was bad for you regardless of what you smoked and I didn’t like the smell anyway. When he got out of the car, he went into a place that didn’t look so much like a store, but more like an alleyway that had several crates stacked up high so you couldn’t really see it from the street. I remember thinking that Ms. -
Name That Street Drug! 1 Instructions
Name That Street Drug! Instructions: Name the substance based on the street names given. Drug Street Names Methamphetamines meth, ice, crank, chalk, crystal, fire, glass, go fast, speed Beannies, blue devils, CR, crystal meth, granulated orange, Mexican crack, pink, rock, speckled birds, speed, tina, and yellow powder Amphetamine bennies, black beauties, crosses, hearts, LA turnaround, speed, truck drivers, and uppers Ritalin/Adderall Ritalin: JIF, MPH, R-ball, Skippy, the smart drug, crackers, one & ones, pharming, poor man’s heroin, ts an ritz, set, speedball, ts & rs, vitamin R, and west coast. Adderall: bennies, black beauties, crosses, hearts, LA turnaround, speed, truck drivers, and uppers Cocaine blow, bump, C, candy, Charlie, coke, crack, flake, rock, snow, toot, do a line, freeze, girl, happy dust, Mama coca, mojo, monster, nose, pimp, shot, smoking gun, sugar, sweet stuff, white powder, base, beat, blast, casper, chalk, devil drug, gravel, hardball, hell, kryptonite, love, moonrocks, rock, scrabble, stones, and tornado Marijuana blunt, dope, ganja, grass, herb, joint, bud, Mary Jane, pot, reefer, green, trees, smoke, sinsemilla, skunk, weed, 420, Aunt Mary, baby, bobby, boom, chira, chronic, ditch, nigra, rip, root, stack, torch, and zambi Synthetic Marijuana K2, Spice, Black Mamba, Blaze, Red X Dawn, Blueberry Haze, Dank, Demon Passion Smoke, Genie, Hawaiian Hybrid, Magma, Ninja, Nitro, Ono Budz, Panama Red Ball, Puff, Sativah Herbal Smoke, Skunk, Ultra Chronic, Voodoo Spice, Bliss, Bombay Blue, Zohai, JWH -018, - 073, -250, -
The Advisability and Feasibility of Developing USP Standards for Medical Cannabis Gabriel I
STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts The Advisability and Feasibility of Developing USP Standards for Medical Cannabis Gabriel I. Giancaspro, Nam-Cheol Kim, Jaap Venema, Susan de Mars, Jennifer Devine, Carlos Celestino, Christine E. Feaster, Ben A. Firschein, Mary S. Waddell, Stephen M. Gardner, and Earl Jones Jr.a ABSTRACT This Stimuli article analyzes the need for public quality standards for medical cannabis (defined herein as marijuana used for medical purposes under state laws) and the potential role of the U.S. Pharmacopeial Convention (USP) in addressing that need.1 Following legalization of the medical use of cannabis in several U.S. states and internationally, USP has received requests to investigate the advisability and feasibility of developing quality standards for medical cannabis. Development of quality standards for medical cannabis requires consideration of a wide range of scientific, legal, and policy issues that reach far beyond its classification as a botanical drug or herbal medicine. This article discusses the current regulatory and scientific landscape regarding medical cannabis, identifies issues related to the lack of quality standards for medical cannabis, and explores potential options for developing quality standards. USP seeks input from stakeholders on whether USP should proceed with development of quality standards for medical cannabis and if so, what approaches should be utilized to establish such standards. LEGAL AND REGULATORY LANDSCAPE The federal and state regulatory environment surrounding the medical use of cannabis involves many federal agencies and various different state laws. The evolving legal environment is an important consideration when evaluating the advisability and feasibility of USP developing a public standard for cannabis. -
TITLE Operation Drug Prevention: a Curriculum Guide K-12
DOCUMENT RESUME ED 068 335 SE 014 904 AUTHOR Martin, William C., Ed. TITLE Operation Drug Prevention: A Curriculum Guide K-12. INSTITUTION University of West Florida, Pensacola. PUB DATE 72 NOTE 287p. EDRS PRICE MF-$0.65 HC-$9.87 DESCRIPTORS Community Action; *Curriculum Guides; *Drug Abuse; *Health Education; *Instructional Materials; Reference Materials ABSTRACT This K-12 sequential curricular program in drug prevention was developed by teachers in six participating countiesin Florida, as a result of the Drug Abuse Education Act passedby the Florida Legislature making such education mandatory in the public schools (K-12) beginning in the 1971-72 schoolyear. This program is based upon the creation of behavior involving the realmsof cognitive, affective, and normative domains, which is hoped will result in the individual's abstinence from theuse of drugs. The program was not written by "experts" in the field of drugs and narcotics nor by a professional writer, but by experiencedclassroom teachers. It was developed as an initial step in devisinga curriculum program and is also offered as a basis fora community action program. Generally, it is written in outline style and organized according to three areas: content, suggestedstudent activities, and resources and materials. Extensive appendixes include a list of slang terms, films, sources, a student dialogue on theuse and abuse of drugs, supplementary materials, directory of health services and agencies, school policies, Florida statutes,etc. A bibliography of books, journals and pamphlets -
A Baseline Review and Assessment of the Massachusetts Adult-Use Cannabis Industry: Market Data and Industry Participation
A Baseline Review and Assessment of the Massachusetts Adult-Use Cannabis Industry: Market Data and Industry Participation February 2020 Massachusetts Cannabis Control Commission: Steven J. Hoffman, Chairman Kay Doyle, Commissioner Jennifer Flanagan, Commissioner Britte McBride, Commissioner Shaleen Title, Commissioner Shawn Collins, Executive Director Prepared by the Massachusetts Cannabis Control Commission Research and Information Technology Departments: Samantha M. Doonan, BA, Research Analyst David McKenna, PhD, Chief Technology Officer Julie K. Johnson, PhD, Director of Research Acknowledgements External Collaborators Alexandra F. Kritikos, MA, Brandeis University Cannabis Control Commission Communications Cedric Sinclair, Director of Communications Maryalice Gill, Press Secretary Kirsten Swenson, Communications Specialist Management Alisa Stack, Chief Operating Officer Erika Scibelli, Chief of Staff Legal Christine Baily, General Counsel Allie DeAngelis, Associate General Counsel Enforcement and Licensing Yaw Gyebi, Chief of Enforcement Paul Payer, Enforcement Counsel Kyle Potvin, Director of Licensing Patrick Beyea, Director of Investigations Derek Chamberlin, Licensing Analyst Anne DiMare, Licensing Specialist Government Affairs David Lakeman, Director of Government Affairs 2 Suggested bibliographic reference format: Doonan SM., McKenna, D., Johnson JK., (2020, February). A Baseline Review and Assessment of the Massachusetts Adult-Use Cannabis Industry— A Report to the Massachusetts Legislature. Boston, MA: Massachusetts Cannabis -
Amicus Brief
SUPREME COURT OF ARIZONA STATE OF ARIZONA, Arizona Supreme Court No. CR-18-0370-PR Appellee, Court of Appeals v. Division One No. 1 CA-CR 16-0703 RODNEY CHRISTOPHER JONES, Yavapai County Appellant. Superior Court No. P1300CR201400328 AMICUS CURIAE BRIEF OF ARIZONA DISPENSARIES ASSOCIATION IN SUPPORT OF APPELLANT (Filed with consent of all parties) Eric M. Fraser (027241) OSBORN MALEDON, P.A. 2929 North Central Avenue, Ste. 2100 Phoenix, Arizona 85012 602-640-9000 [email protected] Attorneys for Amicus Curiae Arizona Dispensaries Association TABLE OF CONTENTS Page TABLE OF AUTHORITIES .................................................................................... 3 INTRODUCTION ................................................................................................... 5 INTEREST OF AMICUS CURIAE ........................................................................ 5 REASONS TO GRANT REVIEW .......................................................................... 6 I. The Opinion warrants review because it will have an enormous impact across Arizona. .............................................................. 6 II. The Opinion upends the industry’s settled expectations. ...................... 7 III. Dispensaries manufacture concentrates using well-known, long-established processes that yield products that satisfy a wide range of patient requirements and preferences. ..........................11 A. Concentrates can be made using extremely simple processes. ...........................................................................................11 -
Kief USA, LLC D/B/A Hui
Kief USA, LLC d/b/a Hui, LLC Community Outreach Meeting Proposal for Marijuana Establishment at Presentation July 7, 2021 1 Turner Street, Attleboro, MA (fka 330 Turner Street, Attleboro, MA) LEADERSHIP Hui Zhang, President, Owner Tucker Cole, Master Grower - Women, Minority Entrepreneur - Over ten years of growing experience in the - First Generation Immigrant Entrepreneur horticulture industry - B.S. in Information Technology from - Over five years of experience in the Cannabis University of Wuhan and Master’s in Industry Financial Accounting from Renmin University - Experience in consulting, facility design, account of China management, research, and breeding of Cannabis Project Team - Managed ten thousand square feet greenhouses - Ali Lee, COO - Legal Advisors: Adam Braillard, Ashley Tan, and Ashfin Islam of Prince Lobel Tye LLP - CSI Engineering LLC, James R. O”Brien, LEED, AP BD+C - Keenan + Kenny Architects LTD, Antonia Kenny CANNABIS IN MASSACHUSETTS Massachusetts Industry Snapshot: ● 8,464 Applications, 794 Licenses ● Total gross sales: $1.47B ● 13,005 Agent Registrations PROPOSED FACILITY ● Marijuana Cultivation and Marijuana Product Manufacturing Establishment ● 1 Turner Street, Attleboro, MA (fka 330 Turner Street) ● Approximately ~84,000 SF on second floor ● Hours: 24/7 hours of cultivation ● 15-20 employees; commitment to use best efforts to hire locally and hire diversity ● At least 21 exclusive Parking Spaces for Hui LLC immediately next to the entrance of the Facility ● Product pickup from secure side loading dock ZONING/LOCATION 1 Turner Street, Attleboro, MA (fka 330 Turner Street) • Industrial Zoning District • Second floor of Existing ~84,000 SF building • 21 exclusive Parking Spaces for the proposed Facility (more available on site) • Building is not within 500 feet of any school (grades K-12), day care, public park, etc. -
Sample Tokyo Kief CAN+
170418-001 page 1 of 1 QA Testing PharmLabs San Diego Certificate of Analysis 3421 Hancock St, Second Floor, San Diego, CA 92110 | License: C8-0000098-LIC ISO/IEC 17025:2017 Certification L17-427-1 | Accreditation #85368 Sample Tokyo Kief Sample ID 170418-001 (21576) Matrix Concentrate (Inhalable Cannabis Good) Tested for MANKIND COOP Sampled - Received Apr 18, 2017 Reported May 16, 2017 Analyses executed CAN+ CAN+ - Cannabinoids Analysis Sample photography | Instrument HPLC-VWD | Method SOP-001 Measurement Uncertainty at 95% confidence 7.806% LOD LOQ Result Result Analyte mg/g mg/g % mg/g Cannabidivarin (CBDV) 0.002 0.16 NT NT Cannabidiolic Acid (CBDA) 0.001 0.16 NT NT Cannabigerol Acid (CBGA) 0.001 0.16 NT NT Cannabigerol (CBG) 0.001 0.16 NT NT Cannabidiol (CBD) 0.001 0.16 0.03 0.29 Tetrahydrocannabivarin (THCV) 0.001 0.16 NT NT Cannabinol (CBN) 0.001 0.16 0.34 3.39 Tetrahydrocannabinol (Δ9-THC) 0.003 0.16 17.24 172.38 Δ8-tetrahydrocannabinol (Δ8-THC) 0.004 0.16 NT NT Cannabicyclol (CBL) 0.002 0.006 NT NT Cannabichromene (CBC) 0.002 0.16 NT NT Tetrahydrocannabinolic Acid (THCA) 0.001 0.16 NT NT Total THC (THCa * 0.877 + THC) 17.24 172.38 Total CBD (CBDa * 0.877 + CBD) 0.03 0.29 TOTAL CANNABINOIDS 17.61 176.10 ND Not Detected Authorized Signature N/A Not Applicable NT Not Reported LOD Limit of Detection LOQ Limit of Quantification <LOQ Detected Jaclyn Mauser - Lab Director >ULOL Above upper limit of linearity CFU/g Colony Forming Units per 1 gram Tue, 16 May 2017 14:25:44 -0700 Accreditation #85368 Scan the QR code to TNTC Too Numerous to Count verify authenticity. -
Download the Patient's Guide To
PATIENT’S GUIDE TO CBD PATIENT'S GUIDE TO CBD AMERICANS FOR SAFE ACCESS 2019 AmericansForSafeAccess.org 1 PATIENT'S GUIDE TO CBD AMERICANS FOR SAFE ACCESS 2019 TABLE OF CONTENTS FOREWORD ...............................................................5 INTRODUCTION ...........................................................8 DEFINITIONS ..............................................................9 CANNABIS SATIVA L.. ......................................................11 AVAILABLE FORMS FOR USE .............................................13 INDICATED USES ..........................................................16 TALKING TO YOUR DOCTOR ABOUT CANNABINOIDS ....................18 FINDING THE RIGHT DOSE. .19 WHAT TO KNOW ABOUT PACKAGING, LABELING, AND HANDLING .....22 THE SUPPLY CHAIN ......................................................30 CHEMICAL STRUCTURE AND ACTIVITY ..................................34 UNDERSTANDING THE ENDOCANNABINOID SYSTEM ...................35 CANNABINOIDS, TERPENES, AND THE ENDOCANNABINOID SYSTEM ...38 FULL-SPECTRUM MEDICINE AND THE ENTOURAGE EFFECT ............38 CERTIFICATIONS AND THE NEED FOR STANDARDS .....................40 CURRENT RESEARCH .....................................................41 CBD ON A GLOBAL SCALE ...............................................42 CONCLUSION ............................................................44 REFERENCES ............................................................45 AMERICANS FOR SAFE ACCESS PATIENT’S GUIDE TO CBD That situation began to change in 1998, however, -
The Maryland Medical Cannabis Commission's Technical Authority
THE MARYLAND MEDICAL CANNABIS COMMISSION’S TECHNICAL AUTHORITY FOR MEDICAL CANNABIS TESTING REVISION 3.0 December 15, 2020 The Maryland Medical Cannabis Commission (MMCC) has developed this technical authority document to define contaminants and corresponding action limits associated with those contaminants in medical cannabis. This information is intended for use by the independent testing laboratories registered with the MMCC. Table of Contents Introduction 3 Sampling 4 Collection Procedure for Laboratory Samples 5 Potency 6 Pesticides 7 Residual Solvents 8 Microbiological Impurities 9 Heavy Metals 11 Excipients 13 Stability Testing 13 Appendix A - Medical Cannabis Testing Requirements 14 Appendix B - Definitions 15 Appendix C - Stability Testing Protocol- MMCC Licensed Grower 17 Appendix D - Stability Testing Protocol-MMCC Licensed Processor 19 Appendix E - Stability Testing Protocol-Edibles 21 Appendix F - Microbiological Quality Control 22 Appendix G- Pathogen Detection Storage Requirements 26 References 27 2 MMCC’s TECHNICAL AUTHORITY FOR MEDICAL CANNABIS TESTING 12/15/20 INTRODUCTION Analytical testing of medical cannabis for safety and potency is increasingly recognized as a critical and necessary component of the industry for several reasons (Freeman et al. 2016): ● Laboratory testing minimizes the risk of pesticides, microbes, heavy metals, toxins, and residual solvents from being consumed by an immunocompromised population; ● Quantification of cannabinoid profiles and potency becomes available for the consumer and aids in determining appropriate dosing for individual use; and ● Laboratory testing provides a sense of public safety and product quality for the medical cannabis tested. The Maryland Medical Cannabis Commission (MMCC), with the assistance of a scientific work group, has established this technical authority to serve as a reference guide for the independent testing laboratories (ITL) to follow when analyzing medical cannabis. -
Bulletin CE2020-01 February 1, 2020
Recreational Marijuana Program Compliance Education Bulletin Bulletin CE2020-01 February 1, 2020 The Oregon Liquor Control Commission is providing the following information to: Recreational marijuana licensees Medical marijuana facilities subject to CTS tracking; and OLCC hemp certificate holders. The bulletin is part of OLCC’s compliance education. It is important that you read it, and understand it. If you don’t understand it please contact the OLCC at [email protected] for help. Failure to understand and follow the information contained in this bulletin could result in an OLCC rules compliance violation affecting your ability to work or operate your business. Bulletin CE2020-01 covers the following issues: Implementation of 2019 legislative changes Technical rule amendments to marijuana regulation effective February 1, 2020. The below summary highlights major rule changes that may affect licensee compliance with certain requirements. This summary is not a comprehensive list of all changes. You can view recent rule changes highlighting changes under “Recent Rule Changes” at https://www.oregon.gov/olcc/marijuana/Pages/Recreational-Marijuana-Laws-and-Rules.aspx The full text of the OLCC’s recreational marijuana rules can be viewed on the Secretary of State webpage at: https://secure.sos.state.or.us/oard/displayDivisionRules.action?selectedDivision=3873 Due to the scope of the changes to OLCC Division 25 rules, this bulletin has been divided into the following sections for ease of reference: Changes for all facilities subject to CTS tracking Changes for all licensees Changes for Producer licensees Changes for Retailer licensees Changes for Laboratory licensees and Hemp Certificate Holders All marijuana compliance bulletins are posted at marijuana.oregon.gov under the “bulletins” section. -
Falling in Love with Mary Jane
Some Housekeeping Rules Before We Begin 10/02/2019 1 OLLI at U of I ©NAR Hello !!! Néstor A. Ramírez, MD, MPH, FAAP OLLI @ University of Illinois October 2, 2019 10/02/2019 OLLI at U of I ©NAR 2 A Brief World History of Cannabis, and America’s On and Off Love Affair with Marijuana, plus A review of Cannabis in Illinois 10/02/2019 OLLI at U of I ©NAR 3 Falling in Love with Mary Jane 10/02/2019 OLLI at U of I ©NAR 4 I’ll Nurture Your Cannabis Cannabis Awareness Brain Lobe Awareness 10/02/2019 OLLI at U of I ©NAR 5 I want to… 10/02/2019 OLLI at U of I ©NAR 6 Disclosures I regret that I have no financial conflicts. I was on the Illinois Medical Cannabis Advisory Board (IMCAB) until Gov. Rauner dissolved it . I am not a user, grower, or dispenser of Cannabis. NO, there will be no free samples today! 10/02/2019 OLLI at U of I ©NAR 7 In the interest of full disclosure, once, when I was 12, I removed the “Do Not Remove Under Penalty of Law” tag from my pillow. 10/02/2019 OLLI at U of I ©NAR 8 DRUG USE DEFINITIONS 10/02/2019 OLLI at U of I ©NAR 9 Tolerance Increasingly larger doses of a drug are required to produce the same effects obtained earlier. 10/02/2019 OLLI at U of I ©NAR 10 Dependence Compulsion to use a drug periodically or continuously to feel its effects and avoid the discomfort of its absence.